Heyholder
‹ Activism Filings

SAMSUNG PHARMACEUTICAL.CO.,Ltd. Q3 revenue KRW 10.2 billion, loss of KRW 2.8 billion from the main business

SAMSUNG PHARMACEUTICAL.CO.,Ltd.· Periodic Report

AI summary · Not investment advice

Samsung Pharm sold KRW 10.2 billion in Q3 and lost KRW 2.8 billion from its main business; sales fell 14.9% from a year earlier and rose 3.1% from the prior quarter.

Operating profit · 3 months

KRW -2.8 billion

Key facts

Revenue (3 months)
KRW 10.2 billion
Net income (3 months)
KRW -7.8 billion
Period
Q3 (cumulative 2026.01.01 ~ 2026.09.30)
Revenue (prior-year 3 months)
KRW 12.0 billion
Revenue (year to date)
KRW 29.1 billion
Operating profit (prior-year 3 months)
KRW -3.9 billion
Operating profit (year to date)
KRW -9.8 billion
Net income (prior-year 3 months)
KRW -30.2 billion
Net income (year to date)
KRW -55.6 billion

Commentary

AI commentary · Not investment advice

What happened

Samsung Pharm reported its separate-basis results for the third quarter of 2026. Sales for the latest 3 months were KRW 10.21 billion. That is down 14.9% from the same 3 months a year earlier, which had KRW 12.00 billion. Sales rose 3.1% from the previous quarter. Cumulative sales this year are KRW 29.13 billion.

In the company's terms

The company made an operating loss (loss from its main business) of KRW 2.80 billion in the latest 3 months. A year earlier, the operating loss for the same period was KRW 3.85 billion. The cumulative operating loss this year is KRW 9.83 billion.

What changes for shareholders

The final result after all costs, taxes and other items was a net loss of KRW 7.75 billion in the latest 3 months. A year earlier, the net loss for the same period was KRW 30.17 billion. The cumulative net loss this year is KRW 55.65 billion.

Comments

No comments yet

Comments from shareholders will appear here.